Send us Fan Mail On this episode of CBmE, Sinead and James interview Associate Professor Saumya Shekhar Jamuar (Senior Consultant in the Genetics Service at KK Women's Children Hospital & Director of the SingHealth Duke-NUS Institute of Precision Medicine). Saumya answer questions about what precision medicine is, whether you should use smart watches to track your health, sharing genomics data in Chinese New Year, Saumya's favourite gene (hint, not boot leg), and an exciting carrier screening test funded by Temasek Foundation, designed to help couples make informed choices in family planning. Remember people, be savvy!
Audio and video play straight from the show's own hosting. PodSubs stores and serves no media.
Transcript
From the show. Tap a time to play from there.
SPEAKER_03The center presents a new podcast at C BME and You, a podcast devoted to promoting awareness and debate around controversial ethical issues in biomedicine.
SPEAKER_05Hello and welcome back to CB Me and You, a podcast by the Center for Biomedical Ethics. Today's topic, precision medicine. What is it? How can it be used? And what are the ethical implications of it? Joining us today is Dr. Samia Jamar, Director of the Singhealth Duke NUS Institute for Precision Medicine, or PRISM.
SPEAKER_00Welcome. Thanks, James Instinate, for this uh warm welcome and for inviting me to talk. I'm very happy to be here.
SPEAKER_04Thank you so much. Um, we're so excited to get into the details today, but we have some more fun questions to get to know you a little bit better. Uh coffee or copy?
SPEAKER_01Copy. Do you have a specific copy order? No, just the regular.
SPEAKER_00Just the regular.
SPEAKER_04Nice, nice.
SPEAKER_00Because uh yeah, so one thing I don't like about Starbucks, they have too many options.
SPEAKER_05It's a bit scary. It's a bit scary. Like you go you go into a coffee shop, you almost feel a bit too basic if you just say, I want a coffee. Yeah, yeah.
SPEAKER_04I'm judging you for that a little.
SPEAKER_05Sinead is our local coffee snob.
SPEAKER_04I'm Australian, what do you expect? Yeah, yeah, yeah.
SPEAKER_00But but yeah, no, I just prefer copy and then they'll be like, copyo? Copy sutai? Copy.
SPEAKER_02Okay. I think like, whoa, we never get that.
SPEAKER_04The judgmental, okay then.
SPEAKER_02W180, okay.
SPEAKER_04Um, next question. What country would you like to travel to the most?
SPEAKER_00So, so actually, I mean, I don't know whether people know, but I grew up in India uh and then I moved to Singapore. And so the country that you know everyone wants to visit is in a way India because the way it's you know is the cultural aspect, the the natural beauty, and all that. And having lived in India, I never managed to encounter that. So India would be one country that I'd like to go back to and as a tourist.
SPEAKER_04Yeah. Uh where in India did you grow up?
SPEAKER_00Uh Delhi.
SPEAKER_04Okay, okay. City center.
SPEAKER_00City centre, yeah. Big city. So so my dad was an academic. So we I used within city centre, I was within the university compound, and so very different from Delhi itself. Uh very serene compared to the hustle and bustle just outside the university campus. Uh have you been to Delhi?
unknownOkay.
SPEAKER_00It's it's it's a madhouse. It's a madhouse.
SPEAKER_04It's I would need some recommendations of where to go before going.
SPEAKER_00I know as much as you do because I haven't okay, I won't say how it's been three decades since I left Delhi.
SPEAKER_04So it's been a long time.
SPEAKER_00It's changed, but and has Singapore been your home since? Yeah. So so most m most of the time, except for two and a half years when I was in Boston doing my genetics training.
SPEAKER_04Oh wow. Okay, cool. Now, my favorite question um uh what song would you sing at karaoke?
SPEAKER_00So it depends on what my daughters are playing. Uh, but I think for me it'll be you two without without you.
SPEAKER_04U2, as in the band U2. Is that is that top chats at the moment?
SPEAKER_00It's not.
SPEAKER_01But that's the song, yeah. You're allowed to like old songs.
SPEAKER_04Well, I just so that my only interaction with with you two was when Apple in like 2010 downloaded all their songs onto everyone's phone without their consent. And so I was really angry about it because I was like, how dare you? This is my phone.
SPEAKER_02Yep, so so maybe that's the reason why? Because I have an old iPhone and it keeps playing without without you.
SPEAKER_04You still have that.
SPEAKER_05So is this really your favorite song to sing, or it's an adapted preference to it? Yeah, they've made it your favorite song.
SPEAKER_00No, it was. I mean, so I used to listen to you two when I was in university before 2010. Uh, and then when Apple did this, it kind of and I love Apple, so Oh, so it's just a coming together of your favorite things.
SPEAKER_02Exactly.
SPEAKER_04Wonderful.
SPEAKER_02And then I was too lazy to delete it. So it's been on a loop since then.
SPEAKER_04Oh wow. Good marketing strategy.
SPEAKER_02They gotcha. Exactly. They got me a hello. Do you know that movie? Do you know that movie? I know it's from a movie. Anyone knows that movie? Jerry Maguire? Tom Cruise?
SPEAKER_04I know Tom Cruise.
SPEAKER_02Okay.
SPEAKER_04I'm so sorry.
SPEAKER_02I know about Jerry Maguire, never saw it.
SPEAKER_04Okay.
SPEAKER_02Okay, show me the money.
SPEAKER_04Yeah, that's that's a famous line. Okay.
SPEAKER_00That's from that movie Jerry Maguire.
SPEAKER_04Okay.
SPEAKER_00Where because he's an agent for this football player.
SPEAKER_04Yeah.
SPEAKER_00And then they're talking about the deal, and he's like, Show me the money.
SPEAKER_04I thought that was a Rihanna song.
SPEAKER_00No, no.
SPEAKER_04Okay.
SPEAKER_00It could also be a Rihanna Rihanna song. But then but then the the the there's a scene where he's trying to ask the uh the female out, and and he just goes on to this rant. She's like, You had me a hello.
SPEAKER_04Oh, okay, okay. Thank you. Thank you for that.
SPEAKER_00Sorry.
SPEAKER_02I'm just dating myself.
SPEAKER_00Okay.
SPEAKER_02Okay.
SPEAKER_04It's okay. You dated me earlier when you know you knew more of the top Spotify songs than I did, so we're even.
SPEAKER_05Yeah, and we all have like one really old movie that we can quote. You know, so mine's like Shrek.
SPEAKER_00If you think Shrek is a really old movie, it is.
SPEAKER_04It came out when I was a kid.
SPEAKER_00So, you know, the one movie that's really number one? Sound of music.
SPEAKER_04Oh, that look, that's fair. Yeah, I respect that.
unknownThank you.
SPEAKER_00Classic.
SPEAKER_05I feel that we've connected. Okay, now that we've defined what an old movie is, it's time to move on to the real questions. To define precision medicine. So, what is precision medicine and how is it different from uh quote unquote normal medicine? I mean, isn't normal medicine something that aims to be precise in the first place?
SPEAKER_00Yeah, so that's a great question. And so uh again, I'm a sort of a history buff. So the word precision medicine was actually coined a while back, but the person who made it famous was Obama. In 2016, he gave a State of the Union speech and he said precision medicine. And that's for the first time. If you look at the Google search for the word precision medicine, it went up like a hundred times. Before that, precision medicine used to be called personalized medicine, which is basically tailoring medications based or treatment based on what the individual needed, right?
SPEAKER_00Unfortunately, medicine as we practice it today, it's a reactive form of medicine where the patient presents to us with the symptom, with the disease. We diagnose that disease and treat them based on what has been shown in a randomized controlled trial of X number of people, shown to benefit 70% of people, cause harm in 30% of people, and we say, look, this is a medication which works for you. Take it, come back in two weeks if you have side effects, come back in three months if you are feeling better.
SPEAKER_00Right? And then we review them. So that's the current state of medicine. Precision medicine turns that around and says, Look, if I can identify who is at risk of developing these side effects, the 30%, then I don't give the medication to them. Right? So I avoid harm. If I can identify the 70% who benefit from this medication, I can ensure that I'm maximizing the use of this medication for the right group of people so they get the benefit and not the ones who won't benefit from it.
SPEAKER_00So precision medicine is about identifying those individuals using different markers, whether it's genomics, whether it's environmental, whether it's their diet, whether there's family history, other omics, and saying which med which treatment option, and medication is just one arm of it, but which treatment option will work best for you as an individual rather than you as a group?
SPEAKER_04So in my head, I'm thinking, okay, so some antibiotics don't work on some people. And at the very basic level, and please correct me, you are trying to identify in advance whether or not this antibiotic will work on this person who it won't work on to make sure that it works the best. But does it work on is it for things other than antibiotics, like more harsh drugs or even just more basic um drugs as well?
SPEAKER_00So antibiotics is a great example because what you're trying to do is based on a person's profile, you're trying to guess what's the organism that's causing that infection and then treating them with that correct antibiotics. Right? So uh if I digress a bit in pediatrics, when you're younger than two, you there's a higher risk for getting infection from what called Streptococcus pneumonia, and that's treated by ampicillin. Whereas if you're older than two, then you get infection through mycoplasma pneumonia, which is treated by erythromycin.
unknownOkay.
SPEAKER_00Right. And so depending on the age group, you kind of say, oh, you're younger than two, you're likely to have streptococcus, I'm gonna give you ampicillin, versus you're older than two, likely mycoplasma, I'm gonna give you erythromycin. So that's but that's that's fair, fairly common, fairly innocuous in some ways, because if you give them an antibiotic and they don't respond, then you change the antibiotic, right? Or sometimes just viral and they don't need antibiotics, right? But when we talk about precision medicine, we're talking, as you rightly said, some of the harsher things, into including chemotherapy, chemotherapeutic drugs.
SPEAKER_00And this is when you want to treat the patient and give them the best chance to fight their cancer. And if you can identify what is the correct medication to give them, right? So one of the examples is this thing called 6 MP or 6 Mercaptopurine. And there are some individuals who don't metabolize that well. You need them to metabolize or break it down into this active product before it becomes uh before it does the job it's supposed to do. And if it doesn't, it causes side effect.
SPEAKER_00So in individuals, you if you can identify who can and who cannot, you may want to avoid the medication because you don't want to give them the side effect.
SPEAKER_04So does this mean that you need like a big database of all the factors about a person, genomic, um, other various traits about the person before this health problem arises? Like, does a patient need to have a lot of tests under them in order for precision medicine to work?
SPEAKER_00Uh so in precision medicine, data is the key. Uh so the more you know, the better you can, the more precise you can be. But one of the things about medicine is it's not it's is as much a science as an art. So we tend to make decisions based on uh incomplete data points, best guess in that sense. And so we don't need to do n number of tests to identify what would be the most appropriate.
SPEAKER_00What we do is what's the most uh basic but also cost-effective option in terms of doing that. So as part of practicing and implementing these into medicine, we need to look at all the aspects, not just the the whether we can whether we have the biomarker, whether we have the right target, but also is this cost-effective, especially at the national level? You have to look at the economics who's paying for this and how do you how do you make sure that it's sustainable? Because you don't want to run out of funds after treating 10 patients and then not be able to treat the next hundred.
SPEAKER_05So if we're trying to collect a lot of data about uh people, uh groups of people or even specific individuals, um, what are the costs involved? Could you say a little bit more about what the costs involved are and how we should try to weigh that against the benefits?
SPEAKER_00So again, the cost when we look at costs, again, uh it's it's uh there's no absolute number, right? It's all relative. As you rightly said, it's weighing the cost of doing something versus the benefit, right? And and so the question goes back to what is the harm that we are causing by imprecise medic imprecise practicing imprecise medic medicine. Uh so one of the harms is that uh a study done in Singapore General Hospital showed that 12.5% of admissions were related to adverse drug reactions.
SPEAKER_00If I could take, identify those individuals without those adverse with those who will develop those adverse drug reactions and make sure that they don't get the adverse drug, I've saved admissions for 12.5% of the patients, right? That's a massive number. Right? So it's it's about taking everything in the context or an entirety and weighing both the pros and the cons. So, yes, there is a cost of generating the data, but the the other thing is there is improvements in technology that are making collecting collection of the data much cheaper by the day.
SPEAKER_00So as we go along, we can right uh data doesn't need to be just through blood samples, it can be through other non-invasive measures. And so many of us wear smart watches, which collects data. Uh, I'm wearing this thing called Aura Ring, uh, which is a smart ring which collects data as well. Uh how?
SPEAKER_05I I thought you talked for a second, I thought you were talking about those rings that you get as a kid, that those so-called mood rings.
SPEAKER_04Yeah, they change color if you're feeling angry or sad.
SPEAKER_00No, no. So this is a this is a sensor. Uh this it's got three sensors at the bottom, and it measures my heart rate, my breathing, uh and and variability in my heart rate.
SPEAKER_04And it's trendy, might I say.
SPEAKER_00Thank you. I'm not advertising for this one.
SPEAKER_04Please just drop the name of the brand.
SPEAKER_00No, that's so these are called smart rings, uh, and essentially uh they take away the pain of having to wear a watch. They're really good at night because they can cap you know, you don't have to wear a watch to sleep, you just wear the ring to sleep. Yeah. Uh the battery lasts longer, so they actually do capture good sleep data. And uh so it's just good to cap to track your sleep pattern. Uh and also the stress level. So after this interview, I'm gonna check on my app what my stress level was. Surprisingly, even though I think I'm fairly relaxed, it says I'm always in a high stress zone.
SPEAKER_04That's interesting. Um, so actually, that leads perfectly into my next question, which is how does precision medicine address patient anxiety and unnecessary unnecessary stress about their health or future health? So, for example, um I've started swimming and I want to start measuring my, like, you know, what my cardiac and respiratory rates and all this sort of stuff, blood pressure. I also want to see if I'm improving. But um, I've been looking at a couple of watches and it's just like there's they track so much data, like your sleep and all these sorts of things.
SPEAKER_04I'm like, I sort of don't want to know how bad my health is. And so I haven't gotten it because I just don't want that kind of anxiety or added stress or added knowing about my life, which means I should be controlling this. Like if I'm aware that it's bad, I should probably fix it. So I'm kind of focusing on ignorance's bliss right now.
SPEAKER_05Yeah, I guess you went over the gym and I'm at the cycling machine, they tell me to put my hands on the sensor so that they can measure my heart rate. And I'm like, I don't want to see my heart rate.
SPEAKER_04I don't need to, I'm doing my best just by being here. I don't need to know that I'm failing as well.
SPEAKER_00Yeah, absolutely. And that actually, in a way, is a bit of precision medicine. It's tailoring what you need in terms of monitoring for your needs. And if that monitoring is going to bring anxiety to you, then maybe it's not the right thing for you. Right? So it's it's understanding that. And that that's a nuance that that's not easy to capture because it's very individual. And a lot of it is also direct to consumer. It's not through a medical practitioner. So what we do as a healthcare professionals is trying to understand and and explain what the different parameters mean, especially when it comes to data collection.
SPEAKER_00When we're collecting data, what would it mean for you to in terms of and and so as part of collecting genetics data, what we do is we do there's this process called genetic counseling, where we actually do, it's it's both done pre-test as well as post-test. And as part of genetic counseling, we actually inform individuals about what it entails through the test, what are the alternatives, what are the risks, what are the benefits, what are the implications? And because genetics is not just about the individual, we share our genetics with our family members.
SPEAKER_00So, what are the implications for your family members if you do find out that you have a genetic condition? And so it's it's it's managing that that anxiety through a process of giving them information and tailoring that recommendation based on the feedback they give on that.
SPEAKER_05So, walk me through the process of uh what would happen to me if I wanted to get into precision medicine. In addition to wearing a ring, what kind of tests would I have to go through? Uh, would I want to go uh through in order to maximize the gains that I get out of precision medicine?
SPEAKER_00So I again, I mean, I think the first thing I would do is, I mean, not to throw a wet blanket, but the fact is that we're not ready, we're not there yet, right? And that's why uh precision medicine is still sort of an a translational research program that the government is funding uh to make Singapore a hub in the future, right? So as part of RIE 2020, they've kind of invested in that. We are currently in phase two, we'll go into phase three. We don't the challenge is we don't have enough data, right?
SPEAKER_00Uh and when when I say we don't have enough data, it's in the past it used to be we don't have enough genomic data, right? Uh it started off with not enough genomic data of the Western population because that's where the funding used to come from. So a lot of data got generated. Then it became a problem of underrepresented populations, rest of the world. That is slowly being solved, and Precise is helping to solve some of that by generating genomic data from healthy individuals. So they're looking at hundred sequencing 100,000 individuals.
SPEAKER_00Beyond genomic data, one of the projects that's being led by NTU is called Helios, where they're saying, look, beyond genomic data, we're gonna collect different biomarkers, we're gonna administer questionnaires, we're gonna collect lifestyle data, give you a watch to kind of monitor your thing. Again, trying to understand what could predict and not predict, right? And and how does that and then doing cost-effective studies to say what will or will not work in a healthcare setting at a national scale, right?
SPEAKER_00So if you ask, if you come to me and say, look, I want to do precision medicine today, I would say yes I can, but it'd be very limited, right? And so when I say it's limited, it's limited to a couple of things. The first thing is that all of us have uh a very we all of us carry variations in our DNA. We have three billion base pairs, we have a variant every thousand base pairs. So all of us on average have between three to five million variants. The good thing is 99.9% of them don't cause disease.
SPEAKER_00They are just there because our ancestors had it, and our ancestors probably got it because there was some environmental pressure that led to favorable selection of that variant that got passed down, right? But what we also know is that in about 3% of individuals who are completely healthy at this point of time, they carry variants in genes that are associated with actionable diseases. So things like BRCA1, BRCA2, right, which is a breast and ovarian cancer gene.
SPEAKER_00Right? These individuals, they don't have cancer, but they will develop cancer in the future. Identifying those individuals early allows us to screen them. When we screen them, we pick the cancer at an early stage, it's curative. If we don't identify them, we don't screen them, by the time they present, the cancer is advanced, the chances of cure are lower. So we change their healthcare outcomes just by identifying them and putting them through a screening program. Right? So that's that's that's one such one example.
SPEAKER_00So 3% of the population have this thing called what we call incidental or secondary findings. And that's what we've been doing at Prism for the past six years, where we've been trying to build workflows to return these incidental findings to participants. The second thing is again looking at variables and all that, again, those are more of nudging behavior rather than actually prescribing anything. But what we showed was that uh when when we compared uh, you know, the cell when as it grows older, there's at the end of this of the chromosome, there's this thing called telomeres.
SPEAKER_00So telomeres tell you how old you are, because when you're young, they are long, when you're old, they're small, shorter, right? And so when we compared individuals by capturing the sleep data using smartwatch and checking their telomeres, what we realized was those individuals who sleep less actually have shorter telomeres for their age.
SPEAKER_04Don't worry, James takes naps every day.
SPEAKER_00Yep. So so when I You have given me the best news. Exactly. And so that's how we we tailor it, right? We say, okay, what's your sleep pattern? Like, what's your sleep hygiene? Let's optimize that. Then we look at nutrition and say, okay, what is your nutrient? You know, how do you and again, the challenge here again is you know, we don't want to overload you with information. Because when we overload information, it's very hard for. For you to keep track of what needs to be keep kept track of, right? And so this is where precision medicine comes in again and say, look, out of the hundred recommendations that I would I would say for any individual, these are the top three priorities for you based on your risk factors.
SPEAKER_00So take those, let's modify that because that reduces your risk in the longer term much more significantly than what's in 97, 98, 99.
SPEAKER_04That seems fairly manageable. If someone said across your entire life, there are just three things you need to do. I feel like maybe I could give it a go.
SPEAKER_05If those three things are exercise more, eat healthier, and sleep more. And sleep more.
SPEAKER_04What are the next ones?
SPEAKER_00All right. So so let's do the other things. So so yeah. So the way we do it is again, I mean, the you know, so it's it's called incremental change, right? So the first thing you do is you do the top three. Once the top three become habit, and and you don't even think about those three, then you go to the next three, right? So so you slowly get to the hundred, but you don't start with hundred right from the start. You start with the top three. And again, the top three may be the hardest one. And so you don't say you don't do you do one, five, and seven, because those are slightly easier to achieve.
SPEAKER_00But you individualize that recommendation based on your risk factors rather than just do it because that's the guidelines.
SPEAKER_04I have a question. So you say there are of the hundred we recommend each person. These are the top three that you should focus on. Do you let them know about that the other 97 exist, or do you withhold that for fear of overwhelming the patient?
SPEAKER_00Uh so that's again a conversation. Again, it's it's it's a it's a very individualized. Uh so in in some in some individuals, when we talk to them, you can see the level of anxiety going up as we give more information. And that's when we say, look, this is not a one-time exercise. It's it's a it's a recurring. And let's stop here, go back, digest this, and come back. We'll see how you're progressing, and then we'll go through the next. Right? So I think one of the key challenges here is in again, as I mentioned, medicine is an art more than science, is recognizing when there's information overload, uh, and then and and then giving the opportunity to get feedback and then and coming back to it at a second in second or third or fourth encounter rather than trying to dump everything at the first encounter.
SPEAKER_00Uh, and and that's something that is very important uh from a doctor-patient relationship. Uh to me, I think the key tenet of a of of having uh helping my patients is to build that trust. Right? I need to I need them to trust that I'm doing what's best for them, not because I just want to see 20 patients and you know, I I want to do what's best for them. Uh and so building that trust helps because for me, even though I have an incomplete conversation on day one, when they come back in three months, I can carry on that conversation uh because I build that trust.
SPEAKER_00So I think that's that's important as well.
SPEAKER_04I have another question and you touched on it a little earlier. But the question is uh you said something about dealing with implications or secondary findings from genetic information, particularly for genes that belong to families. So I can imagine, um, and this is something that's often discussed in bioethics. How or when are you allowed to share information that you discovered through your patient, but has serious and actionable consequences for the family? And what happens and what do you do if the patient says no, you can't share that?
SPEAKER_00Uh so I'll just focus on genetic findings because again, from infectious diseases, there are some acts that you may be familiar with, like HIV and all that. Uh from so from genetic variants, the current stance is it's still dependent on the individual, uh, at least in the local setting. So if I identify someone uh as part of the post-test genetic counseling, what we tell them is this is the risk to your family members. And then what we do is we give them a letter saying, please pass this letter to your family members, and they can contact us and we will do everything else for them, but we can't contact the family members unless the patient consents.
SPEAKER_00Uh, and so what we see is that in the pediatric setting, the families are a bit more open to sharing that information. Uh so if I have a child who has a genetic disorder, uh, and I identify the parents as carriers, they are more willing to let their siblings know because their siblings may be of childbearing age and they may have children with similar disorder. So they want to let the uh which is slightly different experience from the adult setting, where when we tell the adult that, look, you have this and your sibling may have it, they're like, okay.
SPEAKER_00And you go, okay, do you want to give them this letter? Okay. Right? No. And and so it's not. Yeah, yeah. So you get it. Yeah, so so you know in a way it's it's it's harder for adults because they've like, look, uh, yeah. So so what I do is I say, okay, Chinese new year is coming. Besides the young PAO, give this letter as well.
SPEAKER_04Just wrap it in the present.
SPEAKER_01Exactly. It's like what a nice gift. Here's some money. Also, you might be having disease. No, correct.
SPEAKER_00So, and this is where the the challenge is, right? Because you feel that giving that letter means that you're sentencing them to a disease, but actually you're not, right? Because they may not be carrying that variant. The risk is not 100%, the risk is only 50%. So by giving them that letter, and then they come in for testing and they identify that they're not carrying that variant, gives them peace of mind that they won't develop the same disease as their family member.
unknownRight?
SPEAKER_00Otherwise, they're always living in that fear of will I develop heart failure because I have this gene that so affects my heart when I'm 50 years old or not, right? But if I can tell you that it's not, right? And more importantly, it's about the next generation. So when you say, look, this may be something that they may pass on to their children and it manifests differently, so they may be well at this point of time, but the children may manifest more severely, and they may, that's when they say, Oh, okay, actually it makes sense, and then they get come in for testing.
SPEAKER_00So again, we can't force it, but we encourage them and we bring that up. Uh, again, there have been some case laws, and you're probably familiar with it internationally, where family members have sued the doctor for not informing them about their risk because the index patient had a genetic variant. But so far in Singapore there hasn't, and there isn't any um legal precedence on that at this point in time, knock on wood, uh, things change, uh and uh you know uh that's something that we'd have to look at.
SPEAKER_00Um and um and and again, yeah, so we just wait for more guidance on that.
SPEAKER_05Are there some cases where this sort of data has has like some really big public health uh implications? For example, imaginary case here. Uh a patient walks in, you sequence their genome, and you're like, wait a minute, there might be something here that makes them more resistant to COVID or something like that. Uh then you you you might find yourself in a position where where you're like, hey, maybe maybe you should tell somebody, maybe uh get more research done about this.
SPEAKER_04I thought you were going a zombie way, being like, oh, we've identified some zombie genes.
SPEAKER_00You might be a zombie. Yeah, no, no, so so the other way, right? So so I used to run cross-country. So the thing is, it's not about being a zombie or an X-Men. All of us have variation in our DNA, all of us have mutation, and that's why we moved away from using the word mutations, because uh it has a sort of negative, so we call it variance and we call it disease-causing variance versus just benign variants, right? Uh so yes, we definitely have patients who where we find something very interesting.
SPEAKER_00Uh, and so I I have a patient who has cured himself of a disease because he developed a mutation that protects him.
SPEAKER_05Whoa.
SPEAKER_04Wait, wait, wait, right. So he developed the mutation whilst he was alive. Yes. Was he like actively meditating like to bring about this mutation?
SPEAKER_00It is, it is. So, so so I know he's a lovely boy, and I see him once a year, and you know, uh joke with him. But but he's very special because he has a disease that would cause his bone marrow to fail by the time he becomes five. When he was born, he did have uh he he did have failure of his bone marrow, so he wasn't producing enough white cells, he was getting infections, and and that's supposed to progress and continue to deteriorate until their bone marrow completely stops producing and they need a bone marrow transplant.
SPEAKER_00This kid developed a mutation that was just downstream of where the genetic defect was. And so, even though that gene is the instruction manual is missing, it doesn't matter because the process keeps going on because he's got a mutation downstream that turns it on.
SPEAKER_04Evolution in real time.
SPEAKER_00That might be the coolest thing I've heard this week. And so his blood counts are completely normal. I still monitor him because I just want to make sure that it doesn't drop.
SPEAKER_04Yeah, it doesn't mutate back.
SPEAKER_00Yeah. Or or you know, it's always about the balance.
SPEAKER_04Yeah.
SPEAKER_00Uh, and and so far his balance is in the positive side, so he's he's his bone marrow is working. But you know, you never know. So so so that's something. But that's something that happens, right? And so I take it I every time he comes, I take a bit of his sample to see what we can uh how he how he's reacting and stuff and like that. So yes, it happens.
SPEAKER_05Yeah, and are we allowed to I don't know, send that sample off to more labs or do we or try to convince this kid and his parents to agree to more off to the labs with you.
SPEAKER_01Oh no, they're they're completely on board.
SPEAKER_00So so they they they are happy to they're also amazed. Yeah, they're amazed and they're happy to donate the samples because obviously the implications are not just for him, right? But it's it has got implications for the rest of the individuals who have bone marrow failure because of this condition. Yeah. Because if I can identify those individuals and I can give them whatever he has, they may not need to go for bone marrow transplant, they just go for this treatment.
SPEAKER_05I have a kind of like prediction question. I know nobody can make predictions about the future, but uh when do you think uh the average person can walk into a hospital and r ask and go to a doctor and be like, doctor, sequence me, and have a pretty comprehensive, maybe not entirely future predicting, but you know, something like uh getting your palm red, uh a sense of the major obstacles and the major kinds of diseases that we need to look that they need to look out for.
SPEAKER_00So I would say uh today we can be done because the technology is there. We know we have a list of genes that we know are clinically actionable. We know variants in those genes that cause disease. So if you came to my clinic today, I could predict for that subset of diseases whether you are at risk or not. The challenge here is, and this is something that it's it's is that 97% of individuals will not have that risk.
SPEAKER_00And so it leads to disappointment, right? Because now you're paying X amount of dollars to do the test, and then you say, Oh, actually you're healthy.
SPEAKER_02And you'll be surprised at how people take that because I just paid this much stupid healthy body.
SPEAKER_00Correct. So so so I think that's something that again it it's part of that conversation that we do in pretest genetic counseling, is to tell them that look, chances are that you'll come back as healthy. So so you manage your expectations so that if they are 97%, then yes, they're okay. Uh, and that's something to celebrate rather than be sad about. But if they're the 3%, then we can connect them to the specialists that we have, both across the island, right? Uh all three clusters have specialists dealing with those conditions, and we can deal with that and go forward from there.
SPEAKER_00So if you ask me, we can practice precision medicine today uh for the set of conditions called incidental findings. The second thing we can practice, uh uh to some extent we are practicing, but it's the the uh precise is trying to expand on is pharmacogenomics, which we didn't touch on. Pharmacogenomics is how your body reacts. So since 2013, um the Health Sciences Authority, which is the FDA equivalent in Singapore, has mandated that all patients who are being prescribed carbamazepine get tested for this genetic locus called HLAB1502.
SPEAKER_00That's because those who have who are positive for that at that locus have a hundred times higher risk of developing a very severe side effect called Stephen Johnson's, where they peel off their skin, their mucosa, uh, and they end up in ICU and all that. Uh so those individuals, when they're exposed to carbamazepine and they have the HLAB1502 allele, they they may end up with that side effect. So as a risk, and uh it's it's mandated that all patients who have been prescribed carbonozipine we check the HLAB1502.
SPEAKER_00But they at precise they are now trying to expand that to other alleles, which don't have such a severe effect, but yes, they do have, and and seeing how that can be done. So yeah.
SPEAKER_05So I mean, most of us end up dying of some disease or another uh at some point in our life, yeah in our lives. Yeah, is this 3% as time goes on gonna increase to a bigger number? 10%, 50%, 70%, until we can basically discover all the genes that, or most of the genes that that are likely to cause uh some kind of defect in the future?
SPEAKER_00Uh yeah, so absolutely. I mean, I think the idea is again, you know, med medicine is always innovating, uh, or there are innovations in medical technologies to see how we can keep people healthy, right? And and the way I look at it is that precision medicine is not just about individual treatment based on individual risk. All as you rightly said, all of us will eventually die, right? But what happens is that you you in the last 10 years of your life, you develop diseases, and then your last 10 years, you're suffering and you're trying to manage those diseases, right?
SPEAKER_00So, yes, you have a longer life, but you may not have the quality of life. What we're trying to do with precision medicine is improve the quality of that longer life so that you actually have a longer health span where you stay healthy longer before you develop the disease, right? And and so the idea is how do we identify those markers that can predict what the health span should be? So absolutely. So that's something. Uh, and and there's something that we are doing in terms of the next generation is carrier screening, where we're trying to identify individuals who may be at risk of having children with uh carrier screening.
SPEAKER_00And this is where I mentioned all the shout-outs to all the partners who helped us, right? So this is this was based off uh the as the first phase of precise, where they sequenced 10,000 individuals. Uh, our group uh together with the rest of this ecosystem analyzed the data and identified diseases that were commoner in our population uh that were not covered in currently uh commercially available panels. And so we built, together with DXD Hub at ASTAR, we built a panel that was customized to the Asian genome uh to test for carrier uh test for carrier status of individuals.
SPEAKER_00And if both couples are carriers, then they have a high risk of having a child. So in September we launched PREDICT, a program funded by Tamasik Foundation to identify high-risk couples and bring them in for genetic counseling and see how we can help them. Make that the best decision for their family, right? It's not about mandating it, but it's empowering them with knowledge so that they can then make a decision what suits on their personal belief, their moral belief, their religious belief.
SPEAKER_04I feel like the next phase of a project, if there is one, should be called Prime, because then you have like precise predict and then you prime them for the future. You should bring me on. Absolutely.
SPEAKER_05I'm always very impressed about how medical researchers come up with catchy acronyms for everything.
SPEAKER_04And it's very obvious when they fail to do so as well.
SPEAKER_00No, no, so so that's one thing that you have to do when you're applying for funding in Singapore is to find an acronym that's mandated. Yeah, so so so my my clinic, my uh my NMRC grant is called SureFind. Because I'm sure I'll find something. And then uh the next phase is gonna be SureSolve because I found it, now I need to solve it.
SPEAKER_04And how could they not give you the grant? You said you would do it.
SPEAKER_00Exactly. And then the final phase will be sure treat.
unknownOh, that's brilliant.
SPEAKER_00So find solve treat.
SPEAKER_04I love it. I love it. I do have one last question. What is the weirdest gene name you you know of? Because you're mentioning lots of genes. I'm like, I don't remember any from my degree, but surely you remember some funny ones.
SPEAKER_00So so okay, so that not that I can think of right now, but I mean, you know, uh again, gene names are interesting, and and I think the ones that I remember is more from uh from how Excel, which is used to store that the data, modifies the gene names, right? So there's a gene called MAR1 and SEPT1. And so what Excel does is it converts them into dates. So everyone who has a mutation MAR1, it's first March.
SPEAKER_00Everyone who has a mutation CEP1 has first September. And so when you're analyzing that data, you actually miss out on those variants because now Excel has filtered them out. They're not gene names anymore, they're dates. So, so yeah, so so they are uh and I'm sure there are gene names that I can I can't think of right now, but they are uh so I if you ask me, I would say I have my favorite genes.
SPEAKER_04Yes, please, top top one favorite gene. So so the favorite denim, my bad. Sorry, just being jumping.
SPEAKER_00So it's the best gene. The best gene is no no so so so the the secret is that you know when we present uh our work and if it's not been published, then there's a worry of being scooped. So the way genes are named is MFG1, MFG2, and the acronym stands for my favorite gene one, my favorite gene two.
SPEAKER_04Multifactorial genotype.
SPEAKER_00Yeah, so when you present, this is MFG1, and this is how it functions. So nobody knows what it is. Yeah, they just hear the MFG1 and they Google it and they can't find it. But you keep the gene name secret until it gets published because it happens that you are at a conference, you're presenting, and then the guy next to you goes, I know what that gene is. And then you're like, oops, call your postdoc, publish the paper today. Because this guy's publishing it tonight. Right, so so that that's one.
SPEAKER_00Yeah. I my favorite is uh again, it's the first gene that we discovered. It's called DCC. Uh it's uh it's deleted in colorectal carcinoma. It was discovered in 1990, uh, and that that was because it was found to be missing in patients who had colorectal carcinoma. So that's why it's called DCC deleting curve. Five years later, folks realized it had nothing to do with colorectal cancer, it had to do with how your neurons cross the midline. So you know you're left in the right hemisphere, and so what DCC does is it's a receptor.
SPEAKER_00So as the neurons are moving, the receptor is there to say, okay, you need to cross, or no, you stay on this side. So DCC modulates that. And that was shown in the fly model, the mouse model in 1995, 96. And then it took us 25 years to actually prove the first human case. So that was the one of the my so that was my first gene discovery project where we discovered mutation DCC associated with midline crossing defect in individuals, uh in humans.
SPEAKER_04So we thought it was to do with the butt, but it was really the brain.
SPEAKER_01Exactly. Exactly, exactly. I can see the confusion.
SPEAKER_04Yeah. Some people very easily mix those up.
SPEAKER_00So so the fun fact is that you know, DCC, because what happens, you your your neurons don't cross, so your left hemisphere is one and right is another. Uh and so uh again, you know, Rainman, dating back to Dustin Hoffman and Jerry uh and Tom Cruise again. I know this one. So Rainman is about this individual who's autistic. Yeah. And what he does, he can read cards. And that's because he's got this magnificent memory where he can memorize things. Uh, and so it's modeled after an individual, a real life person, who also had a split brain.
SPEAKER_00Uh, we haven't been able to study his DNA, that individual's DNA, but you know, it could be something along their pathway where you've got the left hand and the right brain acting independently. So what you read from the left eye goes to the left brain and right right brain, and then you can read double the Imagine studying for an exam where you can read both pages at the same time. Exactly. So these are these are things that you pick up, you know, these are things that you see. Uh, and these are the extreme ends of the bell curve. You don't have many individuals with that.
SPEAKER_04That was excellent. Fascinating. I think that might also be my favorite gene discovery. Um, so thank you for sharing that. Um, we wanted to thank you so much for coming on the podcast today. This has been a lot of fun.
SPEAKER_00No, no, thank you for having me. I mean, I had fun as well.
SPEAKER_03Thanks for listening to our new podcast. Subscribe online and tune in every first of the month. In the meantime, listen to CBME and U and be savvy.
Send us Fan Mail We spend much of our lives searching for meaning. Some of us look for it at work. Some in our families and friends. Some look for it at an overpriced spiritual retreat in Bali where some dude named...
Send us Fan Mail In some insurance scheme, you might be required to pay more because you are more prone to disability. In another, you may have to pay more because you're a woman (and are statistically likely to live...
Send us Fan Mail Did you know that genomic sequencing can now screen newborns for hundreds of rare conditions right at birth? That looking too closely at our DNA might actually cause more anxiety than answers? And is...
Send us Fan Mail Did you know that over 80% of people who give birth experience an injury? That anywhere between 30 and 50% of people who give birth find it traumatic? And that up to 15% of people experience PTSD from...
Send us Fan Mail Could a blob of cells in a petri dish one day think? Feel? Have rights? In this episode, Professor Insoo Hyun (Harvard Medical School, one of the world's leading experts on the ethics of stem cell and...